A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours

MLA

Melissa Lynne Johnson, et al. “A Phase I, Open-Label, First-Time-in-Patient Dose Escalation and Expansion Study to Assess the Safety, Tolerability, and Pharmacokinetics of Nanoparticle Encapsulated Aurora B Kinase Inhibitor AZD2811 in Patients with Advanced Solid Tumours.” Journal of Clinical Oncology, vol. 35, May 2017, p. TPS2608. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d9ee830f9efa0c4a66a06db39dec5d5e&authtype=sso&custid=ns315887.

APA

Melissa Lynne Johnson, Judy Sing-Zan Wang, Julie Charlton, Wolfram Brugger, Alexander MacDonald, Gerald Steven Falchook, Howard A. Burris, Elizabeth Janet Pease, Carol Greenlees, Donald K Strickland, & Suzanne F. Jones. (2017). A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours. Journal of Clinical Oncology, 35, TPS2608.

Chicago

Melissa Lynne Johnson, Judy Sing-Zan Wang, Julie Charlton, Wolfram Brugger, Alexander MacDonald, Gerald Steven Falchook, Howard A. Burris, et al. 2017. “A Phase I, Open-Label, First-Time-in-Patient Dose Escalation and Expansion Study to Assess the Safety, Tolerability, and Pharmacokinetics of Nanoparticle Encapsulated Aurora B Kinase Inhibitor AZD2811 in Patients with Advanced Solid Tumours.” Journal of Clinical Oncology 35 (May): TPS2608. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d9ee830f9efa0c4a66a06db39dec5d5e&authtype=sso&custid=ns315887.